The ACR’s delegation to the AMA HOD meeting in November successfully advanced resolutions to advocate for pharmacy benefit manager transparency and expanded patient protections from step therapy protocols.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

Year in Review: Rheumatic Disease Research in 2019
ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…

Management of Meniscal Tears: Surgery May Not Be Necessary
Patients with meniscal tear experience similar levels of reduced pain and improved physical function when treated with either arthroscopic partial meniscectomy or physical therapy, according to a recent study. The study also found these improvements were long term—lasting through the five-year follow up…

Leading Boldly: Transforming Rheumatology Campaign Makes Progress
In 2018, the Rheumatology Research Foundation embarked on its third and most ambitious fundraising campaign, Leading Boldly: Transforming Rheumatology, with a goal of raising $75 million over five years. The campaign supports Foundation programs to recruit the best and brightest into the field, train rheumatology professionals at all career stages and support investigators conducting research…

The Look Back: ACR President Dr. Paula Marchetta Recaps 2019
We all have a short list of famous individuals whose writings inspire us and guide us. At the start of my presidential year, I turned to my own short list for some words of wisdom from Peter Drucker, whom many consider to be the founder of modern management theory. Underpinning Drucker’s teachings is a strong…

1 Person Can Make a Difference: The Importance of Advocacy
Your voice matters: That was the shared theme of presentations by Angus Worthing, MD, FACR, FACP, William F. Harvey, MD, MSc, FACR, and Georgia Rep. Kim Schofield (D-Atlanta, Dist. 60) in the session, Raise Your Voice! Advocacy Update from Government Affairs at the 2019 ACR/ARP Annual Meeting on Monday, Nov. 11.

A Farewell Message from Outgoing Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP
A farewell message from outgoing Government Affairs Committee Chair Angus Worthing urges ACR/ARP members to advocate for the rheumatology profession.

Making Rheumatologists’ Voices Count: A Conversation with Blair Solow, MD, Incoming Government Affairs Committee Chair
With multiple healthcare policy issues currently in play, Dr. Solow believes making rheumatologists’ voices heard is crucial to the specialty’s success.

2019 EULAR/ACR SLE Classification Criteria Offer Improved Sensitivity & Specificity
The new EULAR/ACR classification criteria for SLE offer improved sensitivity and specificity, as well as more accurately reflect the current tests used to clinically diagnose SLE. A positive ANA test is obligatory…
Trump Nominates MD Anderson Oncologist as U.S. FDA Commissioner
(Reuters)—U.S. President Donald Trump has nominated Stephen Hahn, MD, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the U.S. Food and Drug Administration (FDA), the White House said on Friday. Dr. Hahn, a radiation oncologist who has been at MD Anderson in Houston since 2015, if confirmed would follow…
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 247
- Next Page »